MCCC2

MCCC2 encodes the non-biotin-containing carboxyltransferase (beta) subunit of mitochondrial 3-methylcrotonyl-CoA carboxylase (MCC), which catalyzes an essential step in leucine catabolism and whose crystal structure reveals a conserved two-step carboxylation mechanism (PMID:22869039). Missense mutations in MCCC2 abolish MCC enzyme activity and cause 3-methylcrotonyl-CoA carboxylase deficiency (PMID:11406611, PMID:14680978). Formation of a catalytically competent MCCC1–MCCC2 heterodimer is promoted by SIRT4-mediated deacetylation of MCCC2 at K269, linking leucine-derived acetyl-CoA production to H3K27 acetylation and tumor-initiating cell properties, while MCCC2 protein turnover is governed by NEDD4-mediated ubiquitin-proteasomal degradation facilitated by ECHDC2 (PMID:40384857, PMID:38783226). In cancer cells, MCCC2 sustains proliferation and invasion through leucine-dependent activation of mTOR and ERK signaling pathways and influences mitochondrial dynamics and telomere length via interaction with TRF2 (PMID:33407468, PMID:41836158, PMID:37828426).

1. 2001 High

   Identification of MCCC2 as the gene encoding the beta subunit of MCC and demonstration that its mutations cause 3-methylcrotonyl-CoA carboxylase deficiency established the molecular basis of this inborn error of leucine metabolism.

   Evidence cDNA cloning, chromosomal mapping, Sanger sequencing of patient alleles, and MCC enzyme activity assay in fibroblasts

   PMID:11406611

   Open questions at the time

   • Structural basis of how beta-subunit mutations disrupt holoenzyme function was unknown
   • Regulation of MCCC2 protein levels and post-translational modifications were uncharacterized
2. 2003 High

   Functional expression of patient-derived MCCC2 missense mutations in MCC-deficient fibroblasts directly confirmed their pathogenicity and showed that conserved residues in the carboxyltransferase subunit are essential for catalytic activity.

   Evidence Transient transfection of mutant MCCC2 into SV40-transformed MCC-deficient fibroblasts with direct MCC enzyme activity readout

   PMID:14680978

   Open questions at the time

   • No high-resolution structure of the holoenzyme was available to map mutation effects
   • Genotype–phenotype correlations across the full mutation spectrum remained incomplete
3. 2012 High

   Crystal structures of the MCC holoenzyme revealed the domain architecture of the MCCC2 beta subunit and provided a structural framework for the two-step carboxylation mechanism and for rationalizing disease-causing mutations.

   Evidence X-ray crystallography of the MCCC1–MCCC2 holoenzyme with structure–function analysis of known mutations

   PMID:22869039

   Open questions at the time

   • Post-translational regulation of complex assembly was not addressed
   • Non-catalytic roles of MCCC2 in cellular signaling were unknown
4. 2021 Medium

   Demonstrating that MCCC2 promotes hepatocellular carcinoma cell proliferation, invasion, and ERK activation through leucine metabolism and acetyl-CoA production expanded its role beyond a housekeeping enzyme to an oncogenic metabolic node.

   Evidence MCCC2 KO/KD in HCC cells, xenograft models, leucine deprivation epistasis, metabolite measurements, mass spectrometry interactome, ERK western blot

   PMID:33407468

   Open questions at the time

   • Direct mechanism linking MCCC2-derived acetyl-CoA to ERK activation was not delineated
   • Whether the oncogenic role is generalizable across tumor types was untested
5. 2023 Medium

   Discovery of a physical MCCC2–TRF2 complex and the finding that MCCC2 loss reduces mitochondrial numbers and telomere length suggested an unexpected role linking mitochondrial dynamics to telomere maintenance.

   Evidence Co-immunoprecipitation of MCCC2 and TRF2, MCCC2 KD/KO in colorectal cancer cells, TEM for mitochondrial morphology, telomere length measurement

   PMID:37828426

   Open questions at the time

   • Co-IP was performed in a single lab without reciprocal validation from an independent group
   • Mechanism by which MCCC2 influences telomere length independently of telomerase is unknown
   • Whether TRF2 interaction requires MCCC2 enzymatic activity was not tested
6. 2024 Medium

   Identification of NEDD4 as the E3 ligase that ubiquitinates MCCC2 — facilitated by ECHDC2 as an adaptor — established the first defined mechanism for MCCC2 protein turnover and linked MCCC2 stability to P38 MAPK-dependent aerobic glycolysis in gastric cancer.

   Evidence Co-immunoprecipitation of ECHDC2–NEDD4–MCCC2 ternary complex, ubiquitination assays, ECHDC2 overexpression in gastric cancer cells, in vivo xenografts

   PMID:38783226

   Open questions at the time

   • Specific ubiquitination sites on MCCC2 were not mapped
   • Whether NEDD4-mediated degradation operates in non-cancer tissues is unknown
7. 2025 Medium

   SIRT4-mediated deacetylation of MCCC2 at K269 was shown to promote stable MCCC1–MCCC2 complex formation, increasing MCC activity, acetyl-CoA output, and downstream H3K27 acetylation that drives tumor-initiating cell properties in HCC.

   Evidence In vitro deacetylation assay, K269 site-directed mutagenesis, co-IP for complex stability, acetyl-CoA and H3K27ac measurements, sphere-forming and invasion assays, in vivo tumor growth

   PMID:40384857

   Open questions at the time

   • Whether K269 acetylation status regulates MCCC2 stability via the NEDD4 pathway was not examined
   • Physiological relevance of SIRT4-MCCC2 axis in normal leucine catabolism remains untested
8. 2026 Medium

   Epistasis experiments in triple-negative breast cancer demonstrated that MCCC2-driven proliferation depends on leucine availability and mTOR signaling, consolidating the leucine–mTOR axis as the dominant oncogenic mechanism downstream of MCCC2.

   Evidence MCCC2 siRNA KD in TNBC cells, rapamycin rescue, leucine-free culture abrogation of phenotype, xenograft tumor growth

   PMID:41836158

   Open questions at the time

   • Direct biochemical link between MCCC2-derived metabolites and mTOR activation (e.g., leucine sensing machinery) is not resolved
   • Contribution of MCCC2 catalytic activity versus scaffolding functions to mTOR activation is unclear

• The integration of MCCC2 post-translational regulation (SIRT4 deacetylation versus NEDD4 ubiquitination) with its non-canonical roles in telomere maintenance and mitochondrial dynamics remains mechanistically unresolved.
• No reconstitution of the MCCC2–TRF2 axis in a non-cancer or physiological model
• How MCCC2 K269 acetylation cross-talks with NEDD4-mediated ubiquitination is unknown
• Structural basis for non-catalytic protein–protein interactions of MCCC2 is lacking